Angiotensin receptor-neprilysin inhibitors

Angiotensin receptor-neprilysin inhibitors has been studied in 45 papers since 2021: 1 trial and 30 observational studies in people, 13 reviews; 31 in the past year. The newest story, Oct 26, 2026: “Empagliflozin reduced heart chamber volumes alongside other drugs”.

Intervention

45 papers study it6 findingsUpdated Oct 26, 2026

28 new papers in 30 daysSee all 45

“ARNI monotherapy showed numerically favorable but non-significant effects on both HFH (HR 0.65, p=0.099) and mortality (HR 0.77, p=0.299).”

Additive benefits of combination ARNI and SGLT2 inhibitor therapy in real-world heart failure: a propensity-weighted analysis of 11,483 asian patientsESC Congress 2026 abstract2026doi:10.1093/eurheartj/ehag785.1275

None of its findings points the other way.

4 independent labs in 4 countries

Human trial1
Humans30

What did studies of Angiotensin receptor-neprilysin inhibitors find?

Studies of Angiotensin receptor-neprilysin inhibitors measured 2 outcomes; the most studied are contrast-associated acute kidney injury (1 study) and heart failure (1).

Contrast-associated acute kidney injury

no changein humans1OR 0.548

1 study

Angiotensin receptor-neprilysin inhibitors have no effect on contrast-associated acute kidney injury in humans (OR 0.548; p=0.127).
“whereas ARNI alone (OR 0.548; p=0.127) and SGLT-2 inhibitor alone (OR 0.782; p=0.423) were not independently associated.”
HumansHeart failure patients undergoing iodinated contrast procedures; adjusted comparison with neither therapyAt least 30 days before the procedure
In heart failure patients, is ARNI and SGLT-2 inhibitor use protective against contrast-associated acute kidney injury?
ESC Congress 2026 abstractOct 26, 2026

More on Contrast-associated acute kidney injury

Heart failure

downin humans1

1 study

Angiotensin receptor-neprilysin inhibitors prevent heart failure in humans.
“treatments, such as angiotensin receptor neprilysin inhibitors, SGLT2i, vericiguat and omecamtiv mecarbil, for preventing heart failure”
Reviewtype 2 diabetesfemales
Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
European cardiologyOct 21, 2021

What is Angiotensin receptor-neprilysin inhibitors linked with?

Studies link Angiotensin receptor-neprilysin inhibitors with 3 measures, most often mortality (1 study), heart failure hospitalization (1) and renal impairment (1).

Mortality

downin humans1HR 0.77

1 study

Angiotensin receptor-neprilysin inhibitors are associated with mortality in humans (Numerically lower mortality; HR 0.77, p=0.299).
“ARNI monotherapy showed numerically favorable but non-significant effects on both HFH (HR 0.65, p=0.099) and mortality (HR 0.77, p=0.299).”
HumansHeart failure; compared with guideline-directed medical therapyMedian 3.1 years
Additive benefits of combination ARNI and SGLT2 inhibitor therapy in real-world heart failure: a propensity-weighted analysis of 11,483 asian patients
ESC Congress 2026 abstractOct 26, 2026

Heart failure hospitalization

downin humans1HR 0.65

1 study

Angiotensin receptor-neprilysin inhibitors are associated with heart failure hospitalization in humans (Numerically lower hospitalization; HR 0.65, p=0.099).
“ARNI monotherapy showed numerically favorable but non-significant effects on both HFH (HR 0.65, p=0.099) and mortality (HR 0.77, p=0.299).”
HumansHeart failure; compared with guideline-directed medical therapyMedian 2.6 years
Additive benefits of combination ARNI and SGLT2 inhibitor therapy in real-world heart failure: a propensity-weighted analysis of 11,483 asian patients
ESC Congress 2026 abstractOct 26, 2026

Renal impairment

upin humans1

1 study

Angiotensin receptor-neprilysin inhibitors raise the risk of renal impairment in humans.
“renal impairment (angiotensin receptor-neprilysin inhibitor use, history of renal dysfunction).”
Humansin patients taking SGLT2 inhibitors and ARNI
Trends in the use of sodium-glucose cotransporter-2 inhibitors and characteristics of adverse event reporting in patients with heart failure in Japan: reports from the medical administration database and the adverse event reporting database
Expert opinion on drug safetyJul 25, 2025

What acts on Angiotensin receptor-neprilysin inhibitors?

Studies name 1 thing that act on Angiotensin receptor-neprilysin inhibitors, most often guideline era (1 study).

Guideline era

upin humans1

1 study

Guideline era increases angiotensin receptor-neprilysin inhibitors in humans (4.1% to 14.3%).
“ARNI use increased from 4.1% in the pre-2016 era to 14.3% in 2021+”
Humansacross guideline eras (pre-2016 vs 2021+)
Temporal trends in incident heart failure medication use and clinical characteristics across guideline eras: a retrospective cohort study
ESC Congress 2026 abstractOct 26, 2026